Incannex Healthcare Reports $46.9 Million Net Loss and Significant Revenue Growth in Fiscal Year 2025

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, reported a net loss of $46.9 million for the fiscal year ended June 30, 2025, a significant increase from the $18.5 million loss in the previous fiscal year. This increase was primarily attributed to $24.3 million in financing activities, including changes in the fair value of warrants and convertible debt, as well as loss on extinguishment of debt during the fiscal year ended June 30, 2025. Revenue from clinic patients for rehabilitation services increased to $86,000, a 617% increase compared to the $12,000 generated in the previous fiscal year, reflecting the expansion of these services.

Research and development expenses decreased to $10.7 million from $12.9 million in the prior year, due to a pause in development activities for resource conservation. General and administrative expenses also decreased to $13.1 million from $17.2 million, primarily due to a decrease in equity compensation and benefits for employees and directors, partially offset by an increase in salaries and other employee benefits, as well as compliance, legal and regulatory expenses. The company received $1.8 million in R&D tax incentives from the Australian government, a substantial decrease from the $11.4 million received in the previous fiscal year.

Key operational developments included the completion of the Phase 2 portion of the RePOSA study, demonstrating statistically and clinically significant improvements across multiple key endpoints for patients receiving IHL-42X compared to placebo. The company is finalizing arrangements for an End of Phase 2 meeting with the FDA to get feedback on planned next steps, including a pivotal Phase 3 trial design. The FDA has completed its review of and cleared the company's IND and gave its authorization for the company to proceed with a Phase 2b clinical trial investigating PSX-001 in patients diagnosed with GAD, with the trial expected to initiate in 2026.

Looking ahead, Incannex expects R&D expenses to increase substantially as it advances its drug candidates through clinical development. The company anticipates needing additional funding to continue these development efforts and may explore strategic partnerships, licensing agreements, and collaboration opportunities. As of June 30, 2025, Incannex had cash and cash equivalents of $15.0 million and believes these resources, along with anticipated cash flows and financing arrangements, will be sufficient to sustain operations for at least one year.